ADVISE

Your introduction to this Phase 2 study investigating the treatment of moderate-to-severe **Atopic Dermatitis (AD)**.

ARENA PHARMACEUTICALS

Care More. Act Differently.

INTRODUCING

ADVISE

An Unmet Need in AD

Patients who currently suffer from AD have limited approved options available from which to choose. Patients suffering from AD need more options and research is needed.

About ADVISE[1]

ADVISE is a Phase 2, multi-center, randomized, double-blinded, placebo-controlled, 16-week study (with a 52-week open-label extension) to assess the safety and efficacy of etrasimod in adult patients with moderate-to-severe atopic dermatitis.

About Etrasimod

Etrasimod is an investigational, small-molecule, orally administered S1P (sphingosine-1-phosphate) receptor modulator that is taken one time a day. In vitro studies have shown etrasimod has activity at receptors $S1P_{1,4,5}$.[2] Etrasimod is an investigational drug and is not currently approved for use by any regulatory agency.

[1]Clinicaltrials.gov NCT04162769

[2]Al-Shamma H, et al. J Pharmacol Exp Ther. 2019;369(3):311–317.

For questions on this ongoing trial, email us at medinfo@arenapharm.com

Study Design



Etrasimod is an investigational drug and is not currently approved for use by any regulatory agency.

Primary Efficacy Endpoint: Percent change in EASI from Baseline to Week 12
Key Secondary Efficacy Endpoints: Proportion of subjects achieving EASI-75 at week 12, Proportion of subjects with a vIGA 0 to 1 (on a 5-point scale) score and a reduction from Baseline of ≥ 2 points at Week 12

Key Inclusion Criteria[3]

Participants may be eligible for the ADVISE trial if they are Adult patients with:

- ✓ Chronic AD (present for >1 year prior to screening)
- ✓ EASI ≥ 12 at screening
- ✓ BSA ≥ 10% of AD involvement
- ✓ vIGA-AD™ score ≥ 3 at screening[4]

EASI: Eczema Area and Severity Index, BSA: Body Surface Area, vIGA-AD: Validated Investigator Global Assessment scale for Atopic Dermatitis.
[3]Arena Data on File, Clinicaltrials.gov NCT04162769
[4]©2017 Eli Lilly and Company – Used with the permission of Eli Lilly and Company under a Creative Commons Attribution-No Derivatives 4.0 International License - https://creativecommons.org/licenses/by-nd/4.0/

ARENA PHARMACEUTICALS

Care More. Act Differently.

For more information, visit
www.arenapharm.com

© 2020 Arena Pharmaceuticals, Inc. Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. All right reserved.

10/2020 MLR-US-AD-0001